{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.98","value":"83.3"},{"groupId":"OG001","spread":"2.12","value":"57.5"},{"groupId":"OG002","spread":"4.04","value":"83.7"},{"groupId":"OG003","spread":"20.95","value":"88.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"description":"Post-treatment neurocognitive function was assessed. Full-scale IQ (FSIQ) is a representative measurement for neurocognitive function. FSIQ was measured by IQ tests. Assessments within the time window, from eligible and evaluable patients are reported. The time window is 30+/-6 months post diagnosis, only the assessments before progression date were reported. The Range of FSIQ is 50-150. A higher FSIQ is better. Mean and standard deviation of FSIQ were calculated and reported.","dispersionType":"Standard Deviation","groups":[{"description":"SPNET patients who received regimen A (no carboplatin / no isotretinoin)","id":"OG000","title":"Regimen A (SPNET Patients)"},{"description":"SPNET patients who received regimen B (carboplatin / no isotretinoin)","id":"OG001","title":"Regimen B (SPNET Patients)"},{"description":"SPNET patients who received regimen C (no carboplatin / isotretinoin)","id":"OG002","title":"Regimen C (SPNET Patients)"},{"description":"SPNET patients who received regimen D (carboplatin / isotretinoin)","id":"OG003","title":"Regimen D (SPNET Patients)"}],"paramType":"MEAN","populationDescription":"Eligible SPNET patients are included","reportingStatus":"POSTED","timeFrame":"24 - 36 months post diagnosis","title":"The Estimated Full-scale IQ (FSIQ) at 30+/-6 Months Post Diagnosis for SPNET Patients","type":"SECONDARY","unitOfMeasure":"Score on a scale"}